Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benoîte Mery1, Samuel Jones2, Alexis Vallard3

  • 1Département d'oncologie médicale, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.

Breast cancer (Tokyo, Japan)·2026
Same author

Adenoid cystic carcinoma of the breast: a case series of 26 patients.

Breast cancer research and treatment·2026
Same author

Feasibility of <i>TP53</i>-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS.

Cancers·2026
Same author

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France.

Drugs - real world outcomes·2026
Same author

ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.

Breast cancer research and treatment·2026
Same author

Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles.

Biomedicines·2025

First-line treatments for metastatic kidney cancer have advanced with targeted therapies and immunotherapy, improving patient survival. Current research focuses on combining these approaches for even better outcomes in clear cell renal cell carcinoma.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic kidney cancer, particularly clear cell renal cell carcinoma (CCRC), is characterized by increased angiogenesis and VEGF signaling.
  • Treatment paradigms have evolved significantly over the last decade.

Purpose of the Study:

  • To review first-line treatment recommendations for metastatic kidney cancer.
  • To present findings from recent clinical trials in this area.

Main Methods:

  • Review of current literature and clinical trial data on first-line treatments for metastatic renal cell carcinoma.
  • Analysis of targeted therapies and immunotherapies.

Main Results:

  • Tyrosine kinase inhibitors (TKIs) and immunotherapy have transformed first-line treatment strategies.
Keywords:
AngiogenesisAngiogénèseCancer du reinImmunotherapiesImmunothérapiesMetastaticMétastatiqueRenal cancerTargeted therapiesThérapies ciblées

Related Experiment Videos

  • New anti-angiogenic molecules are now prioritized based on histology and prognostic groups, leading to improved survival.
  • Ongoing trials explore combinations of targeted therapies with immune checkpoint inhibitors and various immunotherapies.

    • Conclusions:

    • First-line treatment for metastatic kidney cancer has been revolutionized by targeted therapies and immunotherapy.
    • These advancements have significantly improved patient survival rates.
    • Future directions involve optimizing treatment sequencing and exploring novel combination therapies.